Mody Avani A, Wordinger Robert J, Clark Abbot F
North Texas Eye Research Institute, University North Texas Health Science Center, Fort Worth, Texas, United States.
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):849-859. doi: 10.1167/iovs.16-20472.
Increased expression of TGF-β2 in primary open-angle glaucoma (POAG) aqueous humor (AH) and trabecular meshwork (TM) causes deposition of extracellular matrix (ECM) in the TM and elevated IOP. Bone morphogenetic proteins (BMPs) regulate TGF-β2-induced ECM production. The underlying mechanism for BMP4 inhibition of TGF-β2-induced fibrosis remains undetermined. Bone morphogenic protein 4 induces inhibitor of DNA binding proteins (ID1, ID3), which suppress transcription factor activities to regulate gene expression. Our study will determine whether ID1and ID3 proteins are downstream targets of BMP4, which attenuates TGF-β2 induction of ECM proteins in TM cells.
Primary human TM cells were treated with BMP4, and ID1 and ID3 mRNA, and protein expression was determined by quantitative PCR (Q-PCR) and Western immunoblotting. Intracellular ID1 and ID3 protein localization was studied by immunocytochemistry. Transformed human TM cells (GTM3 cells) were transfected with ID1 or ID3 expression vectors to determine their potential inhibitory effects on TGF-β2-induced fibronectin and plasminogen activator inhibitor-I (PAI-1) protein expression.
Basal expression of ID1-3 was detected in primary human TM cells. Bone morphogenic protein 4 significantly induced early expression of ID1 and ID3 mRNA (P < 0.05) and protein in primary TM cells, and a BMP receptor inhibitor blocked this induction. Overexpression of ID1 and ID3 significantly inhibited TGF-β2-induced expression of fibronectin and PAI-1 in TM cells (P < 0.01).
Bone morphogenic protein 4 induced ID1 and ID3 expression suppresses TGF-β2 profibrotic activity in human TM cells. In the future, targeting specific regulators may control the TGF-β2 profibrotic effects on the TM, leading to disease modifying IOP lowering therapies.
原发性开角型青光眼(POAG)房水(AH)和小梁网(TM)中转化生长因子-β2(TGF-β2)表达增加会导致TM中细胞外基质(ECM)沉积及眼压升高。骨形态发生蛋白(BMP)调节TGF-β2诱导的ECM生成。BMP4抑制TGF-β2诱导的纤维化的潜在机制仍未明确。骨形态发生蛋白4诱导DNA结合蛋白抑制剂(ID1、ID3),其抑制转录因子活性以调节基因表达。我们的研究将确定ID1和ID3蛋白是否为BMP4的下游靶点,BMP4可减弱TGF-β2诱导的TM细胞中ECM蛋白的生成。
用BMP4处理原代人TM细胞,通过定量PCR(Q-PCR)和Western免疫印迹法测定ID1和ID3 mRNA及蛋白表达。通过免疫细胞化学研究细胞内ID1和ID3蛋白的定位。用ID1或ID3表达载体转染转化的人TM细胞(GTM3细胞),以确定它们对TGF-β2诱导的纤连蛋白和纤溶酶原激活物抑制剂-I(PAI-1)蛋白表达的潜在抑制作用。
在原代人TM细胞中检测到ID1-3的基础表达。骨形态发生蛋白4显著诱导原代TM细胞中ID1和ID3 mRNA(P<0.05)及蛋白的早期表达,且一种BMP受体抑制剂可阻断这种诱导。ID1和ID3的过表达显著抑制TM细胞中TGF-β2诱导的纤连蛋白和PAI-1的表达(P<0.01)。
骨形态发生蛋白4诱导的ID1和ID3表达抑制人TM细胞中TGF-β2的促纤维化活性。未来,靶向特定调节因子可能会控制TGF-β2对TM的促纤维化作用,从而带来降低眼压的疾病改善疗法。